Table 3.

Multivariable-adjusted associations of Adipokines (Exam 2/3) with incident CAC (Exam 5)

	Incidence rate ratios (95% CI)
	Model 1	Model 2	Model 2b	Model 3	Model 3b
Leptin
Tertile 1	Reference	Reference	Reference	Reference	Reference
Tertile 2	1.24 (0.94, 1.63)	1.12 (0.84, 1.48)	1.15 (0.82, 1.62)	1.12 (0.83, 1.51)	1.19 (0.83, 1.72)
Tertile 3	1.48 (1.08, 2.05)	1.05 (0.71, 1.56)	1.00 (0.62, 1.60)	1.05 (0.70, 1.58)	1.01 (0.62, 1.66)
Resistin
Tertile 1	Reference	Reference	Reference	Reference	Reference
Tertile 2	1.02 (0.81, 1.28)	1.01 (0.80, 1.26)	1.00 (0.77, 1.30)	1.05 (0.83, 1.32)	1.04 (0.80, 1.36)
Tertile 3	0.94 (0.73, 1.20)	0.91 (0.71, 1.17)	0.91 (0.69, 1.22)	0.96 (0.74, 1.24)	1.00 (0.74, 1.35)
Adiponectin
Tertile 1	Reference	Reference	Reference	Reference	Reference
Tertile 2	0.87 (0.68, 1.11)	0.93 (0.73, 1.19)	0.95 (0.71, 1.27)	1.00 (0.78, 1.28)	1.03 (0.76, 1.38)
Tertile 3	0.87 (0.67, 1.13)	0.99 (0.76, 1.29)	1.04 (0.76, 1.44)	1.25 (0.94, 1.66)	1.28 (0.92, 1.79)

Adipokines and covariates were obtained at MESA visits 2 or 3 (randomly assigned) which was the baseline for this analysis.

Incident coronary artery calcification (CAC) was defined as CAC >0 Agatston units at exam 5 and measured using multivariable-adjusted Poisson regression with robust variance estimation.

Model 1: adjusted for age, sex, race/ethnicity and study site

Model 2: model 1 + education (dichotomized), physical activity, smoking, pack-years of smoking and body mass index.

Model 2b: Model 2 + visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT).

Model 3: model 2 + systolic blood pressure, anti-hypertensive medication, total cholesterol, HDL-cholesterol, lipid-lowing medication, diabetes mellitus, and estimated glomerular filtrate rate.

Model 3b: Model 3: VAT and SAT.

Results in bold font indicate statistical significance at p <0.05.